Cargando…

Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response

Dedifferentiated chondrosarcomas (DDCS) are aggressive tumors with poor outcomes. Treatment of localized DDCS is primarily surgical, though most patients present with unresectable or metastatic disease. Systemic treatment options for advanced DDCS are limited, and the benefits of chemotherapy in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Amisha, Thorpe, Steven W., Darrow, Morgan, Carr-Ascher, Janai R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713241/
https://www.ncbi.nlm.nih.gov/pubmed/36465334
http://dx.doi.org/10.3389/fonc.2022.991724
_version_ 1784841974750117888
author Singh, Amisha
Thorpe, Steven W.
Darrow, Morgan
Carr-Ascher, Janai R.
author_facet Singh, Amisha
Thorpe, Steven W.
Darrow, Morgan
Carr-Ascher, Janai R.
author_sort Singh, Amisha
collection PubMed
description Dedifferentiated chondrosarcomas (DDCS) are aggressive tumors with poor outcomes. Treatment of localized DDCS is primarily surgical, though most patients present with unresectable or metastatic disease. Systemic treatment options for advanced DDCS are limited, and the benefits of chemotherapy in this patient population remain controversial. Among other systemic therapy options, there is emerging clinical evidence to support the use of immunotherapy in patients with advanced DDCS. However, studies regarding the efficacy of immunotherapy in advanced DDCS are limited. Here, we present the case of a patient with metastatic, programmed death-ligand 1 (PD-L1)-positive DDCS treated with pembrolizumab who showed a sustained complete response for 24 months after initiation of therapy. To our knowledge, this case represents one of few documented cases of metastatic chondrosarcoma with sustained response to immunotherapy. The impressive response seen with PD-L1 inhibition in our patient indicates that immunotherapy is a successful treatment option in a subset of DDCS patients, and further investigation is needed to identify potential responders to immunotherapy.
format Online
Article
Text
id pubmed-9713241
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97132412022-12-02 Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response Singh, Amisha Thorpe, Steven W. Darrow, Morgan Carr-Ascher, Janai R. Front Oncol Oncology Dedifferentiated chondrosarcomas (DDCS) are aggressive tumors with poor outcomes. Treatment of localized DDCS is primarily surgical, though most patients present with unresectable or metastatic disease. Systemic treatment options for advanced DDCS are limited, and the benefits of chemotherapy in this patient population remain controversial. Among other systemic therapy options, there is emerging clinical evidence to support the use of immunotherapy in patients with advanced DDCS. However, studies regarding the efficacy of immunotherapy in advanced DDCS are limited. Here, we present the case of a patient with metastatic, programmed death-ligand 1 (PD-L1)-positive DDCS treated with pembrolizumab who showed a sustained complete response for 24 months after initiation of therapy. To our knowledge, this case represents one of few documented cases of metastatic chondrosarcoma with sustained response to immunotherapy. The impressive response seen with PD-L1 inhibition in our patient indicates that immunotherapy is a successful treatment option in a subset of DDCS patients, and further investigation is needed to identify potential responders to immunotherapy. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9713241/ /pubmed/36465334 http://dx.doi.org/10.3389/fonc.2022.991724 Text en Copyright © 2022 Singh, Thorpe, Darrow and Carr-Ascher https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Singh, Amisha
Thorpe, Steven W.
Darrow, Morgan
Carr-Ascher, Janai R.
Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
title Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
title_full Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
title_fullStr Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
title_full_unstemmed Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
title_short Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
title_sort case report: treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713241/
https://www.ncbi.nlm.nih.gov/pubmed/36465334
http://dx.doi.org/10.3389/fonc.2022.991724
work_keys_str_mv AT singhamisha casereporttreatmentofmetastaticdedifferentiatedchondrosarcomawithpembrolizumabyieldssustainedcompleteresponse
AT thorpestevenw casereporttreatmentofmetastaticdedifferentiatedchondrosarcomawithpembrolizumabyieldssustainedcompleteresponse
AT darrowmorgan casereporttreatmentofmetastaticdedifferentiatedchondrosarcomawithpembrolizumabyieldssustainedcompleteresponse
AT carrascherjanair casereporttreatmentofmetastaticdedifferentiatedchondrosarcomawithpembrolizumabyieldssustainedcompleteresponse